SCHEMBL6099341

SCHEMBL6099341

Oc1ccc2c(Cl)cnnc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.40
TTR P02766 2/20 0.39
ESR1 P03372 8/20 0.38
ESR2 Q92731 8/20 0.38
HSP90AA1 P07900 1/20 0.38
ESRRB O95718 1/20 0.38
ESRRA P11474 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
ENPP2 Q13822 1/20 0.35
PDE10A Q9Y233 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663828 0.85 ESR1 (0.49) HSD17B10TTRESR1ESR2HSP90AA1
SCHEMBL15028830 0.80 NR4A2 (0.40) HSD17B10ALDH1A1MAPTALOX15
Hydrochloric Acid SCHEMBL15010418 0.78 NR4A2 (0.39) HSD17B10ESR1ESR2ALDH1A1MAPT
SCHEMBL4398975 0.77 LMNA (0.42) KDM4EALDH1A1PDE10ALMNAMAPT
SCHEMBL17075876 0.77 NT5E (0.38) HTTSMN1; SMN2
SCHEMBL30462865 0.77 NT5E (0.38) HTTSMN1; SMN2
SCHEMBL6840380 0.75 ALDH1A1 (0.40) KDM4EALDH1A1HPGDPDE10AMAPT
SCHEMBL11196001 0.74 ALDH1A1 (0.46) HSD17B10ESR1ESR2CA12CA1
SCHEMBL4387662 0.73 CYP1A2 (0.36)
SCHEMBL3375367 0.73 CYP1A2 (0.42) HSD17B10KDM4EALDH1A1PDE10ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087602-B2 Cinnoline derivatives and use as medicine ASTRAZENECA UK LIMITED (GB) 2006-08-08 US disclosed
EP-0888310-B1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ASTRAZENECA AB (SE) 2005-09-07 EP disclosed
US-20030199513-A1 Cinnoline derivatives and use as medicine ZENECA LIMITED 2003-10-23 US disclosed
US-6514971-B1 For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans ZENECA LIMITED (GB) 2003-02-04 US disclosed
EP-0888310-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1999-01-07 EP disclosed
WO-1997034876-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199513-A1 Cinnoline derivatives and use as medicine VEGFA, CNR1, CCR7 HSD17B10 1286/4885TTR 1885/4885ESR1 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.